ABBOTT LABORATORIES (ABL.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ABL - US0028241000 - Common Stock
105.18 EUR
-0.46 (-0.44%)
We assign a fundamental rating of 6 out of 10 to ABL. ABL was compared to 63 industry peers in the Health Care Equipment & Supplies industry. ABL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. While showing a medium growth rate, ABL is valued expensive at the moment. These ratings would make ABL suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year ABL was profitable.
ABL had a positive operating cash flow in the past year.
ABL had positive earnings in each of the past 5 years.
ABL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ABL (16.60%) is better than 92.06% of its industry peers.
ABL has a Return On Equity of 27.43%. This is amongst the best in the industry. ABL outperforms 93.65% of its industry peers.
The Return On Invested Capital of ABL (9.90%) is better than 77.78% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ABL is in line with the industry average of 9.81%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROIC | 9.9% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
1.3 Margins
ABL has a Profit Margin of 31.88%. This is amongst the best in the industry. ABL outperforms 98.41% of its industry peers.
In the last couple of years the Profit Margin of ABL has grown nicely.
ABL has a better Operating Margin (18.29%) than 76.19% of its industry peers.
In the last couple of years the Operating Margin of ABL has grown nicely.
Looking at the Gross Margin, with a value of 56.19%, ABL is in line with its industry, outperforming 49.21% of the companies in the same industry.
ABL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% |
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
2. Health
2.1 Basic Checks
ABL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ABL has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ABL has less shares outstanding
The debt/assets ratio for ABL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.66 indicates that ABL is not in any danger for bankruptcy at the moment.
ABL has a Altman-Z score of 5.66. This is amongst the best in the industry. ABL outperforms 88.89% of its industry peers.
The Debt to FCF ratio of ABL is 1.87, which is an excellent value as it means it would take ABL, only 1.87 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.87, ABL belongs to the best of the industry, outperforming 82.54% of the companies in the same industry.
ABL has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
ABL has a better Debt to Equity ratio (0.23) than 68.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 5.66 |
ROIC/WACC1.17
WACC8.43%
2.3 Liquidity
ABL has a Current Ratio of 1.70. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
ABL has a Current ratio of 1.70. This is comparable to the rest of the industry: ABL outperforms 52.38% of its industry peers.
ABL has a Quick Ratio of 1.24. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
ABL has a Quick ratio (1.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
ABL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.40%, which is quite good.
The Earnings Per Share has been growing slightly by 7.59% on average over the past years.
Looking at the last year, ABL shows a small growth in Revenue. The Revenue has grown by 6.37% in the last year.
ABL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.63% yearly.
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
3.2 Future
ABL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.89% yearly.
The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.57, the valuation of ABL can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ABL indicates a somewhat cheap valuation: ABL is cheaper than 69.84% of the companies listed in the same industry.
ABL's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.28.
Based on the Price/Forward Earnings ratio of 21.38, the valuation of ABL can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ABL is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 23.52. ABL is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.57 | ||
| Fwd PE | 21.38 |
4.2 Price Multiples
ABL's Enterprise Value to EBITDA is on the same level as the industry average.
65.08% of the companies in the same industry are more expensive than ABL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.82 | ||
| EV/EBITDA | 19.65 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.15
PEG (5Y)3.24
EPS Next 2Y10.8%
EPS Next 3Y10.58%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.88%, ABL has a reasonable but not impressive dividend return.
ABL's Dividend Yield is a higher than the industry average which is at 2.14.
ABL's Dividend Yield is comparable with the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
5.2 History
The dividend of ABL is nicely growing with an annual growth rate of 11.40%!
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
ABL pays out 28.93% of its income as dividend. This is a sustainable payout ratio.
The dividend of ABL is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
FRA:ABL (12/9/2025, 7:00:00 PM)
105.18
-0.46 (-0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners81.17%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap182.89B
Revenue(TTM)43.84B
Net Income(TTM)13.98B
Analysts79.43
Price Target124.8 (18.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
Yearly Dividend1.9
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)-1.38%
PT rev (3m)0.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0.15%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.57 | ||
| Fwd PE | 21.38 | ||
| P/S | 4.86 | ||
| P/FCF | 30.82 | ||
| P/OCF | 23.38 | ||
| P/B | 4.18 | ||
| P/tB | 9.97 | ||
| EV/EBITDA | 19.65 |
EPS(TTM)4.28
EY4.07%
EPS(NY)4.92
Fwd EY4.68%
FCF(TTM)3.41
FCFY3.24%
OCF(TTM)4.5
OCFY4.28%
SpS21.63
BVpS25.14
TBVpS10.55
PEG (NY)2.15
PEG (5Y)3.24
Graham Number49.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROCE | 11.52% | ||
| ROIC | 9.9% | ||
| ROICexc | 11.13% | ||
| ROICexgc | 21.33% | ||
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% | ||
| FCFM | 15.78% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
ROICexc(3y)12.18%
ROICexc(5y)11.89%
ROICexgc(3y)32.65%
ROICexgc(5y)35.03%
ROCE(3y)12.16%
ROCE(5y)11.86%
ROICexgc growth 3Y-24.08%
ROICexgc growth 5Y-8.19%
ROICexc growth 3Y-10.71%
ROICexc growth 5Y6.04%
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 81.77% | ||
| Profit Quality | 49.49% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 5.66 |
F-Score7
WACC8.43%
ROIC/WACC1.17
Cap/Depr(3y)63.63%
Cap/Depr(5y)61.92%
Cap/Sales(3y)4.94%
Cap/Sales(5y)5.1%
Profit Quality(3y)82.78%
Profit Quality(5y)99.6%
High Growth Momentum
Growth
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
EBIT growth 1Y15.18%
EBIT growth 3Y-6.62%
EBIT growth 5Y8.41%
EBIT Next Year27.08%
EBIT Next 3Y15.42%
EBIT Next 5Y13.66%
FCF growth 1Y53.98%
FCF growth 3Y-9.78%
FCF growth 5Y7.14%
OCF growth 1Y39.24%
OCF growth 3Y-6.69%
OCF growth 5Y6.88%
ABBOTT LABORATORIES / ABL.DE FAQ
What is the fundamental rating for ABL stock?
ChartMill assigns a fundamental rating of 6 / 10 to ABL.DE.
What is the valuation status for ABL stock?
ChartMill assigns a valuation rating of 3 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Overvalued.
What is the profitability of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of ABBOTT LABORATORIES (ABL.DE) stock?
The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 24.57 and the Price/Book (PB) ratio is 4.18.
Can you provide the financial health for ABL stock?
The financial health rating of ABBOTT LABORATORIES (ABL.DE) is 7 / 10.